ATS1002

ATS1002 is a bispecific antibody-drug conjugate (ADC) designed to target both Claudin 18.2 (CLDN18.2) and Human Epidermal Growth Factor Receptor 2 (HER2). Developed by AbTis and Dong-A ST, it utilizes an enhanced knob-into-hole (eKiH) interface to ensure precise bispecific assembly. The drug is specifically engineered to overcome the challenge of target heterogeneity in gastric cancer, where tumor cells may express only one of the targets or show mosaic expression patterns. ATS1002 can be conjugated with various cytotoxic payloads, including monomethyl auristatin E (MMAE) or exatecan (a topoisomerase I inhibitor), and has demonstrated potent anti-tumor activity in preclinical models by effectively internalizing in cells expressing either or both targets.